What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025Blood

Efficacy and safety of CAR-T cell therapy versus bispecific antibodies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: A single-arm meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

Meta-analysis evaluates efficacy and safety of CAR-T therapy and bispecific antibodies, suggesting CAR-T shows better efficacy in B-cell lymphoma.

CAR-T therapy demonstrated higher efficacy than bispecific antibodies, achieving an objective response rate of 72%.
The study included 59 phase I/II clinical trials with a total of 2,914 participants, assessing the safety and effectiveness of treatments.
Among adverse events, CAR-T therapy had a higher incidence of cytokine release syndrome and neurotoxicity compared to bispecific antibodies.
Findings indicate that while CAR-T is more effective, bispecific antibodies may offer a better safety profile for patients.

Shiji Wang (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Meta-analysis evaluates efficacy and safety of CAR-T therapy and bispecific antibodies, suggesting CAR-T shows better efficacy in B-cell lymphoma.

CAR-T therapy demonstrated higher efficacy than bispecific antibodies, achieving an objective response rate of 72%.
The study included 59 phase I/II clinical trials with a total of 2,914 participants, assessing the safety and effectiveness of treatments.
Among adverse events, CAR-T therapy had a higher incidence of cytokine release syndrome and neurotoxicity compared to bispecific antibodies.
Findings indicate that while CAR-T is more effective, bispecific antibodies may offer a better safety profile for patients.

Shiji Wang (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark